

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE****RECEIVED  
CENTRAL FAX CENTER****AUG 31 2004**Applicants Docket Number:  
**USST01010 US CNT**Applicants:  
**Cecile Combeau, et al**

Serial No.

**10/659,094**Filing Date:  
**September 10, 2003**Title of Invention:  
**Compounds Derived From Oxindoles and Their Therapeutic  
Application in Cancer Treatment****CERTIFICATE OF TRANSMISSION**I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at (703) 872-9306, onDate of Deposit August 31, 2004Printed Name of Person Signing Certificate Maribel MendezSignature Maribel Mendez**Total Number of Pages Sent: 3**Attorney: **Joseph Strupczewski**Group Art Unit: **1626**  
Examiner: **Waller, Robin Regina**TO: Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- ☐ Amendment, 37 CFR \_\_\_\_\_  
☐ Charge deposit account, in duplicate  
☐ Extension of Time Petition  
☐ Issue Fee Transmittal & Advance Order

- ☐ Fee Transmittal  
☐ Petition under 37 CFR \_\_\_\_\_  
☐ Other \_\_\_\_\_  
☒ Other Election of Invention And Request  
For Reconsideration And Withdrawal of  
Restriction Requirements Under 37  
C.F.R. 1.143 (2 pgs.)

- ☐ Maintenance Fee Transmittal

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

**BEST AVAILABLE COPY**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**